Production (Stage)
Rakovina Therapeutics Inc.
RKV.V
TSX
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 74.92% | 42.19% | 24.57% | 0.51% | -10.03% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 49.82% | 22.42% | 2.02% | -10.04% | -15.21% |
| Operating Income | -49.82% | -22.42% | -2.02% | 10.04% | 15.21% |
| Income Before Tax | -53.04% | -29.35% | -11.47% | 2.02% | 9.91% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -53.04% | -29.35% | -11.47% | 2.02% | 9.91% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -53.04% | -29.35% | -11.47% | 2.02% | 9.91% |
| EBIT | -49.82% | -22.42% | -2.02% | 10.04% | 15.21% |
| EBITDA | -63.90% | -28.81% | -2.77% | 12.05% | 17.93% |
| EPS Basic | -27.80% | -20.45% | -11.11% | 2.03% | 10.06% |
| Normalized Basic EPS | -27.17% | -20.83% | -11.49% | 1.63% | 9.90% |
| EPS Diluted | -26.42% | -11.34% | -7.12% | -1.33% | 2.92% |
| Normalized Diluted EPS | -27.17% | -20.83% | -11.49% | 1.63% | 9.90% |
| Average Basic Shares Outstanding | 18.37% | 7.55% | 0.43% | 0.10% | 0.01% |
| Average Diluted Shares Outstanding | 18.37% | 7.55% | 0.43% | 0.10% | 0.01% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |